DIAGNOSIS FOR BAP SUPPLEMENTAL BENEFITS

Similar documents
Case 2:12-md AB Document Filed 10/06/14 Page 1 of 61 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA

SENATE, No STATE OF NEW JERSEY. 217th LEGISLATURE INTRODUCED MARCH 14, 2016

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DEMENTIA, THE BRAIN AND HOW IT WORKS AND WHY YOU MATTER

Dementia Prepared by: Joanne Leung Psychiatry Resident, University of Toronto

Medicare Part C Medical Coverage Policy

Neuropsychological Testing (NPT)

Last month, roughly 100 million people watched the

8/24/18. Dementia. Risk of Dementia Following Traumatic Brain Injury: A Review of the Literature. Media Presence. Media Presence

Community Information Forum September 20, 2014

Understanding Mental Health Preadmission Screening and Resident Review (PASRR) and Form Valerie Krueger Mental Health PASRR Specialist

Cognitive Assessment 4/29/2015. Learning Objectives To be able to:

Disclosures 7/22/2015 MANAGEMENT OF SPORTS RELATED CONCUSSION. Brad Herskowitz MD Neurologist Baptist Hospital

CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE

Neuropsychology and Parkinson s Disease. Erin Holker, Ph.D., ABPP Neuropsychology Laboratory

Annex A TITLE 49. PROFESSIONAL AND VOCATIONAL STANDARDS PART I. DEPARTMENT OF STATE. Subpart A. PROFESSIONAL AND OCCUPATIONAL AFFAIRS

Working with Your. Neurologist

WHEREAS, the Tennessee General Assembly finds that thousands of Tennesseans are

Reports of the INS - Division 40 Task Force on Education, Accreditation, and Credentialing

SENATE BILL lr0870 CF 8lr1286 A BILL ENTITLED

Your legacy. Their cure. The Brain Tissue Resource Facility

Kevin Guskiewicz is the Kenan Distinguished Professor and founding director of the

Nervous System Document Based Questions (DBQ)

ALZHEIMER S DISEASE OVERVIEW. Jeffrey Cummings, MD, ScD Cleveland Clinic Lou Ruvo Center for Brain Health

Sports Concussion After the Injury. Carol Scott, MD UNR Student Health Center Sports Medicine September 22, 2016

(Bill No. 2) An Act to Amend the Workers Compensation Act (No. 2)

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

Concussion. Concussion

No An act relating to health insurance coverage for early childhood developmental disorders, including autism spectrum disorders. (S.

PRINCE GEORGE S COUNTY PUBLIC SCHOOLS Board of Education Upper Marlboro, Maryland Policy No. BOARD OF EDUCATION POLICY

Review Evaluation of Residuals of Traumatic Brain Injury (R-TBI) Disability Benefits Questionnaire * Internal VA or DoD Use Only*

Explaining Unpredictable Emotional Episodes

Brain Concussion: A Stealth Injury. Christine Schulman, RN, MS, CNS, CCRN Trauma & Critical Care CNS Legacy Health, Portland, Oregon Director, AACN

Trajectories of different cognitive domains in community-dwelling older adults

PUBLIC POLICIES AND ALZHEIMER RESEARCH

16 SB 319/AP. Senate Bill 319 By: Senators Jackson of the 2nd, Kirk of the 13th, Unterman of the 45th, Henson of the 41st and Orrock of the 36 th

ADMINISTRATIVE POLICY AND PROCEDURE

Sports Related Concussions. The King-Devick Test: the Science & Implementation

Dementia: It s Not Always Alzheimer s

CHAPTER Committee Substitute for Committee Substitute for Senate Bill No. 2760

Applied Behavior Analysis for Autism Spectrum Disorders

Concussion. Concussion is a disturbance of brain function caused by a direct or indirect force to the head.

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

Neuropsychological Testing Coverage Guidelines

Policy \ \ Medical (Palliative) Use of Marijuana

Referrer Resource Pack. Neurocognitive Clinic

IC Chapter 4. Indiana Tobacco Use Prevention and Cessation Trust Fund

Conflicts. Objectives. You can t hide. Epidemiology 4/16/2018. I have no relevant financial relationships to disclose.

Improving the Methodology for Assessing Mild Cognitive Impairment Across the Lifespan

DSM-5 MAJOR AND MILD NEUROCOGNITIVE DISORDERS (PAGE 602)

ISO INTERNATIONAL STANDARD. Non-destructive testing Qualification of personnel for limited applications of non-destructive testing

September 30, Eric BASTINGS, MD. Acting Director Division of Neurology Products (DNP) Center for Drug Evaluation and Research (CDER)

Cognitive Impairment - Parkinson's Disease Foundation (PDF)

South Carolina General Assembly 122nd Session,

Speech perception in individuals with dementia of the Alzheimer s type (DAT) Mitchell S. Sommers Department of Psychology Washington University

Plan for Today. Brain Injury: 8/4/2017. Effective Services for People Living with Brain Injury. What is it & what causes it?

NACC Minimum Data Set (MDS) Public Data Element Dictionary

September 12, Richard Hodges Director, Ohio Department of Health 246 N. High St. Columbus, Ohio 43215

MEDICAL POLICY No R4 NEUROPSYCHOLOGICAL AND PSYCHOLOGICAL TESTING

NEUROPSYCHOLOGY TRACK COORDINATOR: Dr. Ellen Vriezen

Texas Administrative Code

Anxiety, Depression, and Dementia/Alzheimer Disease: What are the Links?

Concussion in Sport: Current Options for Assessment and Treatment. Naomi L. Albertson, M.D. Family Medicine/Sports Medicine Reno Orthopaedic Clinic

Training for Memory Screeners

2018 CONCUSSION UPDATE WHAT S NEW? 4/12/2018. Michele LaBotz MD FAAP InterMed Sports Medicine AAP Council on Sports Medicine and Fitness

MUSCULOSKELETAL AND NEUROLOGICAL DISORDERS

CIGARETTE TAX, TOBACCO ESCROW FUNDS MASTER SETTLEMENT AGREEMENT, TOBACCO PRODUCTS TAX

Be it enacted by the People of the State of Illinois,

CHAPTER 64B5-12 CONTINUING PROFESSIONAL EDUCATION

EXECUTIVE BRAIN HEALTH. Revolutionary Technology & the Region s Most Advanced Clinical Assessment of Cognitive Performance & Brain Health

Service Related Project. Kimberley Keegan

NOTICE OF APPEAL OR PETITION

Concussion: Not Just For Athletes

High School Football and Risk of Neurodegeneration: A Community-Based Study

CHAPTER Section 3 of P.L.1983, c.296 (C.45: ) is amended to read as follows:

Medical Marijuana and Student Health. New England College Health Association Gordon H. Smith, Esq. October 30, 2014

The Ethics of Working with Aging Donors

Table e-1. MCI diagnosis criteria used by articles included in AAN MCI guideline. MCI diagnosis criteria used by included articles

Supports for. Dementia

Nuedexta (dextromethorphan hydrobromide/quinidine sulfate)

AD8 DEMENTIA SCREENING INTERVIEW

RFP FOR SETTLEMENT IN THE NATIONAL COLLEGIATE ATHLETIC ASSOCIATION STUDENT- ATHLETE CONCUSSION INJURY LITIGATION

Membership Information and Application

Concussion Update and Case Presentations

Covered Critical Illness Conditions Appendix Effective Date: March 1, 2010

The Legalization of Medical Marijuana and the Impact on the Workplace

Specialised Services Policy: CP23 Vagal Nerve Stimulation

COGNITIVE ALTERATIONS IN CHRONIC KIDNEY DISEASE K K L E E

RESIDENTIAL SERVICE PROTECTION FUND

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Recognizing Dementia can be Tricky

Policy / Drug and Alcohol-Free Workshops

TITLE: Endophenotypes of Dementia Associated with Traumatic Brain Injury in Retired Military Personnel

(Legal document Do not reproduce or distribute)

Chronic Traumatic Encephalopathy Provider and Parent Essentials

Workplace Issues Associated with Legalized Marijuana. James B. Yates, Esq., SHRM-SCP, SPHR

45:14G-1 Short title. 1.This act shall be known and may be cited as the "Polysomnography Practice Act."

Applied Behavior Analysis Medical Necessity Guidelines

Diagnosis and assessment

Form D1: Clinician Diagnosis

Transcription:

INJURY DEFINITIONS DIAGNOSIS FOR BAP SUPPLEMENTAL BENEFITS Level 1 Neurocognitive Impairment of Level 1 Neurocognitive Impairment must meet the criteria set forth in subsections (i)-(iv) informant, or the Qualified BAP Provider that there has been a decline in cognitive function. (ii) Evidence of moderate cognitive decline from a previous level of performance, as determined by and in accordance with the standardized neuropsychological testing protocol annexed in Exhibit 2 to the Settlement Agreement, in two or more cognitive domains (complex attention, executive function, learning and memory, language, perceptualspatial), provided one of the cognitive domains is (a) executive function, (b) learning and memory, or (c) complex attention. Clinical Dementia Rating scale Category 0.5 (Questionable) in the areas of Community Affairs, Home & Hobbies, and Personal Care. (b) Level 1 Neurocognitive Impairment, for the purposes of this Settlement Agreement, may only be diagnosed by Qualified BAP Providers during a BAP baseline assessment examination, with agreement on the diagnosis by the Qualified BAP Providers. Exhibit 1, as amended Page 1

QUALIFYING DIAGNOSES FOR MONETARY AWARDS 1. Level 1.5 Neurocognitive Impairment of Level 1.5 Neurocognitive Impairment must meet the criteria set forth in subsections (i)-(iv) informant, or the Qualified BAP Provider that there has been a severe decline in cognitive function. (ii) Evidence of a moderate to severe cognitive decline from a previous level of performance, as determined by and in accordance with the standardized neuropsychological testing protocol annexed in Exhibit 2 to the Settlement Agreement, in two or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-spatial), provided one of the cognitive domains is (a) executive function, (b) learning and memory, or (c) complex attention. Clinical Dementia Rating (CDR) scale Category 1.0 (Mild) in the areas of Community Affairs, Home & Hobbies, and Personal Care. Such functional impairment shall be corroborated by documentary evidence (e.g., medical records, employment records), the sufficiency of which will be determined by the physician making the Qualifying Diagnosis. In the event that no documentary evidence of functional impairment exists or is available, then (a) there must be evidence of moderate to severe cognitive decline from a previous level of performance, as determined by and in accordance with the standardized neuropsychological testing protocol annexed in Exhibit 2 to the Settlement Agreement, in the executive function cognitive domain or the learning and memory cognitive domain, and at least one other cognitive domain; and (b) the Retired NFL Football Player s functional impairment, as described above, must be corroborated by a third-party sworn affidavit from a person familiar with the Retired NFL Football Player s condition (other than the player or his family members), the sufficiency of which will be determined by the physician making the Qualifying Diagnosis. (b) For living Retired NFL Football Players diagnosed outside of the BAP, a diagnosis while living of Level 1.5 Neurocognitive Impairment, i.e., early dementia, based on evaluation and evidence generally consistent with the diagnostic criteria set forth in subsection 1(a)(i)-(iv) above, made by a Qualified MAF Physician or a board-certified or otherwise qualified neurologist, neurosurgeon, or other neuro-specialist physician, as set forth and provided in Sections 6.3(b)-(d) of the Settlement Agreement. (c) For Retired NFL Football Players deceased prior to the Effective Date, a diagnosis of Level 1.5 Neurocognitive Impairment, i.e., early dementia, based on evaluation and evidence generally consistent with the diagnostic criteria set forth in subsection 1(a)(i)-(iv) Exhibit 1, as amended Page 2

above, made while the Retired NFL Football Player was living by a board-certified or otherwise qualified neurologist, neurosurgeon, or other neuro-specialist physician, or by a physician with sufficient qualifications in the field of neurology or neurocognitive disorders, as set forth and provided in Sections 6.3(c)-(e) of the Settlement Agreement. 2. Level 2 Neurocognitive Impairment of Level 2 Neurocognitive Impairment must meet the criteria set forth in subsections (i)-(iv) informant, or the Qualified BAP Provider that there has been a severe decline in cognitive function. (ii) Evidence of a severe cognitive decline from a previous level of performance, as determined by and in accordance with the standardized neuropsychological testing protocol annexed in Exhibit 2 to the Settlement Agreement, in two or more cognitive domains (complex attention, executive function, learning and memory, language, perceptualspatial), provided one of the cognitive domains is (a) executive function, (b) learning and memory, or (c) complex attention. Clinical Dementia Rating (CDR) scale Category 2.0 (Moderate) in the areas of Community Affairs, Home & Hobbies, and Personal Care. Such functional impairment shall be corroborated by documentary evidence (e.g., medical records, employment records), the sufficiency of which will be determined by the physician making the Qualifying Diagnosis. In the event that no documentary evidence of functional impairment exists or is available, then (a) there must be evidence of severe cognitive decline from a previous level of performance, as determined by and in accordance with the standardized neuropsychological testing protocol annexed in Exhibit 2 to the Settlement Agreement, in the executive function cognitive domain or the learning and memory cognitive domain, and at least one other cognitive domain; and (b) the Retired NFL Football Player s functional impairment, as described above, must be corroborated by a thirdparty sworn affidavit from a person familiar with the Retired NFL Football Player s condition (other than the player or his family members), the sufficiency of which will be determined by the physician making the Qualifying Diagnosis. (b) For living Retired NFL Football Players diagnosed outside of the BAP, a diagnosis while living of Level 2 Neurocognitive Impairment, i.e., moderate dementia, based on evaluation and evidence generally consistent with the diagnostic criteria set forth in subsection 2(a)(i)-(iv) above, unless the diagnosing physician can certify in the Diagnosing Physician Certification that certain testing in 2(a)(i)-(iv) is medically unnecessary because the Retired NFL Football Player s dementia is so severe, made by a Qualified MAF Physician or a board-certified Exhibit 1, as amended Page 3

or otherwise qualified neurologist, neurosurgeon, or other neuro-specialist physician, as set forth and provided in Sections 6.3(b)-(d) of the Settlement Agreement. (c) For Retired NFL Football Players deceased prior to the Effective Date, a diagnosis of Level 2 Neurocognitive Impairment, i.e., moderate dementia, based on evaluation and evidence generally consistent with the diagnostic criteria set forth in subsection 2(a)(i)-(iv) above, unless the diagnosing physician can certify in the Diagnosing Physician Certification that certain testing in 2(a)(i)-(iv) was medically unnecessary because the Retired NFL Football Player s dementia was so severe, made while the Retired NFL Football Player was living by a physician, or by a physician with sufficient qualifications in the field of neurology or neurocognitive disorders, as set forth and provided in Sections 6.3(c)-(e) of the Settlement Agreement. 3. Alzheimer s Disease specific disease of Alzheimer s Disease as defined by the World Health Organization s International Classification of Diseases, 9th Edition (ICD-9), the World Health Organization s International Classification of Diseases, 10th Edition (ICD-10), or a diagnosis of Major Neurocognitive Disorder due to probable Alzheimer s Disease as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), made by a Qualified MAF Physician or a physician, as set forth and provided in Sections 6.3(b)-(d) of the Settlement Agreement. diagnosis of Major Neurocognitive Disorder due to probable Alzheimer s Disease consistent with the definition in Diagnostic and Statistical Manual of Mental Disorders (DSM-5), or a diagnosis of Alzheimer s Disease, made while the Retired NFL Football Player was living by a physician, or by a physician with sufficient qualifications in the field of neurology to make such a diagnosis, as set forth and provided in Sections 6.3(c)-(e) of the Settlement Agreement. 4. Parkinson s Disease specific disease of Parkinson s Disease as defined by the World Health Organization s International Classification of Diseases, 9th Edition (ICD-9), the World Health Organization s International Classification of Diseases, 10th Edition (ICD-10), or a diagnosis of Major Neurocognitive Disorder probably due to Parkinson s Disease as defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), made by a Qualified MAF Physician or a physician, as set forth and provided in Sections 6.3(b)-(d) of the Settlement Agreement. diagnosis of Parkinson s Disease, made while the Retired NFL Football Player was living by a Exhibit 1, as amended Page 4

physician, or by a physician with sufficient qualifications in the field of neurology to make such a diagnosis, as set forth and provided in Sections 6.3(c)-(e) of the Settlement Agreement. 5. Death with Chronic Traumatic Encephalopathy (CTE) For Retired NFL Football Players who died prior to the Final Approval Date, a post-mortem diagnosis of CTE made by a board-certified neuropathologist prior to the Final Approval Date, provided that a Retired NFL Football Player who died between July 7, 2014 and the Final Approval Date shall have until 270 days from his date of death to obtain such a postmortem diagnosis. 6. Amyotrophic Lateral Sclerosis (ALS) specific disease of Amyotrophic Lateral Sclerosis, also known as Lou Gehrig s Disease ( ALS ), as defined by the World Health Organization s International Classification of Diseases, 9th Edition (ICD-9) or the World Health Organization s International Classification of Diseases, 10th Edition (ICD-10), made by a Qualified MAF Physician or a board-certified or otherwise qualified neurologist, neurosurgeon, or other neuro-specialist physician, as set forth and provided in Sections 6.3(b)-(d) of the Settlement Agreement. diagnosis of ALS, made while the Retired NFL Football Player was living by a board-certified or otherwise qualified neurologist, neurosurgeon, or other neuro-specialist physician, or by a physician with sufficient qualifications in the field of neurology to make such a diagnosis, as set forth and provided in Sections 6.3(c)-(e) of the Settlement Agreement. Exhibit 1, as amended Page 5